SlideShare une entreprise Scribd logo
1  sur  1
Télécharger pour lire hors ligne
All Types
of NCL
Canine Models for NCL Therapy Development
Martin L. Katz and Gary S. Johnson, School of Medicine and College of Veterinary Medicine, University of Missouri
Introduction:
Dog models for the neuronal ceroid lipofuscinoses (NCLs or
Batten disease) will be useful for evaluating the efficacy of
potential therapeutic interventions for treating these diseases.
The NCLs result from mutations in at least 13 different genes.
Different approaches to therapy are going to be required to
treat the different forms of NCL. Therefore, it will be important
to have suitable animal models for each of the forms of NCL.
A dog model for the CLN2 form of Batten disease played a
critical role in the development of an effective enzyme
replacement therapy currently being used to treat children with
this disorder. This has proven the utility of dog models in pre-
clinical studies required before approval can be obtained for
conducting human clinical trials. Our goal is to develop dog
models for each of the forms of NCL that can be used for
therapeutic intervention testing in preparation for conducting
human clinical trials.
Acknowledgements: This work was made possible by the many dog owners who contributed samples from their pets and the veterinarians who collected postmortem tissues. Numerous
research personnel contributed to the disease characterizations and mutation identifications. Among them are Tomoyuki Awano, Douglas Sanders, Dennis O’Brien, Liz Hansen, Fabiana
Farias, Jenny Guo, Douglas Gilliam, and Ana Kolicheski. Others who contributed to this work are listed on the laboratory website http://medicine.missouri.edu/neurodegenerativediseases/publications.php
Support for some of this work was provided by the BDSRA and the American Kennel Club Canine Health Foundation.
Establishing Canine NCL Models:
Naturally occurring canine NCLs identified to date: Significance:
• A Dachshund model for the CLN2 form of NCL
was used to demonstrate the efficacy of enzyme
replacement therapy that resulted in the recent
successful completion of human clinical trials of
this treatment in children by BioMarin
Pharmaceutical.
• Using this same model, gene therapy to the
central nervous system was also found to be
effective in treating this disease. This method of
treatment may be tested in children in the future.
• Currently we have preserved canine semen for the
CLN2 and CLN5 forms of Batten disease.
• We are screening dogs with the other forms of
NCL to obtain semen as a resource for breeding
affected dogs.
• We also continue to search for dogs with different
forms of NCL that correspond to the remaining
forms of NCL. We have DNA samples from
several other dog breeds with NCL for which we
are seeking to causative mutation.
• We plan to establish a canine NCL models
resource center that will be able to generate dogs
affected with each of the forms of NCL.
• We developed a panel of biomarkers of NCL
disease progression in dogs that can be used in
testing for the therapeutic efficacy of treatments
using the dog models.

Contenu connexe

Tendances

SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017 Kristen Brennand
SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017   Kristen BrennandSCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017   Kristen Brennand
SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017 Kristen Brennandwef
 
FOLDING (Central dogma of genetics)
FOLDING (Central dogma of genetics) FOLDING (Central dogma of genetics)
FOLDING (Central dogma of genetics) Maria Giraldo
 
Screening Of Mdr1 [Autosaved]
Screening Of  Mdr1 [Autosaved]Screening Of  Mdr1 [Autosaved]
Screening Of Mdr1 [Autosaved]Pooja1923
 

Tendances (20)

2016 BDSRA Shyng, Nelvagal, Dearborn, Cooper, Sands CLN1
2016 BDSRA Shyng, Nelvagal, Dearborn, Cooper, Sands CLN12016 BDSRA Shyng, Nelvagal, Dearborn, Cooper, Sands CLN1
2016 BDSRA Shyng, Nelvagal, Dearborn, Cooper, Sands CLN1
 
BDSRA 2015 CLN2 Schulz, Miller, Mole, Cohen
BDSRA 2015 CLN2 Schulz, Miller, Mole, CohenBDSRA 2015 CLN2 Schulz, Miller, Mole, Cohen
BDSRA 2015 CLN2 Schulz, Miller, Mole, Cohen
 
BDSRA 2015 Gene Therapy for the Eye, Mole
BDSRA 2015 Gene Therapy for the Eye, MoleBDSRA 2015 Gene Therapy for the Eye, Mole
BDSRA 2015 Gene Therapy for the Eye, Mole
 
BDSRA 2015 CLN10 Burrow, Spaeth, Sisk, Hallinan
BDSRA 2015 CLN10 Burrow, Spaeth, Sisk, HallinanBDSRA 2015 CLN10 Burrow, Spaeth, Sisk, Hallinan
BDSRA 2015 CLN10 Burrow, Spaeth, Sisk, Hallinan
 
BDSRA 2015 CLN6 Mole
BDSRA 2015 CLN6 MoleBDSRA 2015 CLN6 Mole
BDSRA 2015 CLN6 Mole
 
2012 ANCL Smith, Dahl, Damiano. Bahlo &Berkovic
2012 ANCL Smith, Dahl, Damiano. Bahlo &Berkovic2012 ANCL Smith, Dahl, Damiano. Bahlo &Berkovic
2012 ANCL Smith, Dahl, Damiano. Bahlo &Berkovic
 
2016 BDSRA Whiting & Katz CLN2
2016 BDSRA Whiting & Katz CLN22016 BDSRA Whiting & Katz CLN2
2016 BDSRA Whiting & Katz CLN2
 
BDSRA 2015 CLN1 Wishart
BDSRA 2015 CLN1 Wishart BDSRA 2015 CLN1 Wishart
BDSRA 2015 CLN1 Wishart
 
BDSRA 2015 CLN3 Kielian
BDSRA 2015 CLN3 KielianBDSRA 2015 CLN3 Kielian
BDSRA 2015 CLN3 Kielian
 
2016 BDSRA Williams, Adams, Blohm, Cohen-Pfeffer, de los Reyes, Denecke, Drag...
2016 BDSRA Williams, Adams, Blohm, Cohen-Pfeffer, de los Reyes, Denecke, Drag...2016 BDSRA Williams, Adams, Blohm, Cohen-Pfeffer, de los Reyes, Denecke, Drag...
2016 BDSRA Williams, Adams, Blohm, Cohen-Pfeffer, de los Reyes, Denecke, Drag...
 
2013 Vlincl lehesjoki
2013 Vlincl lehesjoki2013 Vlincl lehesjoki
2013 Vlincl lehesjoki
 
CLN8 Pesaola 2013
CLN8 Pesaola 2013CLN8 Pesaola 2013
CLN8 Pesaola 2013
 
2014 BDSRA Mole JNCL
2014 BDSRA Mole JNCL2014 BDSRA Mole JNCL
2014 BDSRA Mole JNCL
 
2017 BDSRA Tammen, Grupen, James and Delerue CLN6 CLN7
2017 BDSRA Tammen, Grupen, James and Delerue CLN6 CLN72017 BDSRA Tammen, Grupen, James and Delerue CLN6 CLN7
2017 BDSRA Tammen, Grupen, James and Delerue CLN6 CLN7
 
2012 CLN5 Boustany
2012 CLN5 Boustany2012 CLN5 Boustany
2012 CLN5 Boustany
 
2017 BDSRA Whiting and Katz CLN2
2017 BDSRA Whiting and Katz CLN22017 BDSRA Whiting and Katz CLN2
2017 BDSRA Whiting and Katz CLN2
 
SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017 Kristen Brennand
SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017   Kristen BrennandSCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017   Kristen Brennand
SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017 Kristen Brennand
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
FOLDING (Central dogma of genetics)
FOLDING (Central dogma of genetics) FOLDING (Central dogma of genetics)
FOLDING (Central dogma of genetics)
 
Screening Of Mdr1 [Autosaved]
Screening Of  Mdr1 [Autosaved]Screening Of  Mdr1 [Autosaved]
Screening Of Mdr1 [Autosaved]
 

Similaire à 2016 BDSRA Katz & Johnson All NCL types

Preclinical drug discovery and development
Preclinical drug discovery and developmentPreclinical drug discovery and development
Preclinical drug discovery and developmentsamthamby79
 
antibody engineering and xenotransplantation
antibody engineering and xenotransplantation antibody engineering and xenotransplantation
antibody engineering and xenotransplantation Karla Mae Manalo
 
236 Understanding Systemic Lupus Erythematosus. A Qualitative Study Of Women ...
236 Understanding Systemic Lupus Erythematosus. A Qualitative Study Of Women ...236 Understanding Systemic Lupus Erythematosus. A Qualitative Study Of Women ...
236 Understanding Systemic Lupus Erythematosus. A Qualitative Study Of Women ...Wendy Berg
 
Aspect of-stem-cell-based-therapies-kwang-yul-cha
Aspect of-stem-cell-based-therapies-kwang-yul-chaAspect of-stem-cell-based-therapies-kwang-yul-cha
Aspect of-stem-cell-based-therapies-kwang-yul-chaJohn Redaelli
 
Animal Models for Therapeutic Strategies
Animal Models for Therapeutic StrategiesAnimal Models for Therapeutic Strategies
Animal Models for Therapeutic StrategiesReportsnReports
 
M.Sc; Transgenic mice as a model of human diseases.pptx
M.Sc; Transgenic mice as a model of human diseases.pptxM.Sc; Transgenic mice as a model of human diseases.pptx
M.Sc; Transgenic mice as a model of human diseases.pptxSiddharthaSarkar49
 
Lessons from-geron 2014
Lessons from-geron 2014Lessons from-geron 2014
Lessons from-geron 2014Leah Krevitt
 

Similaire à 2016 BDSRA Katz & Johnson All NCL types (20)

2017 BDSRA Katz and Whiting All forms
2017 BDSRA Katz and Whiting All forms2017 BDSRA Katz and Whiting All forms
2017 BDSRA Katz and Whiting All forms
 
2017 BDSRA Hughes, Best, Wicky, Clare, Cheong, Yip, Biggs and Mace CLN5 CLN6
2017 BDSRA Hughes, Best, Wicky, Clare, Cheong, Yip, Biggs and Mace CLN5 CLN62017 BDSRA Hughes, Best, Wicky, Clare, Cheong, Yip, Biggs and Mace CLN5 CLN6
2017 BDSRA Hughes, Best, Wicky, Clare, Cheong, Yip, Biggs and Mace CLN5 CLN6
 
2018 BDSRA Cotman MGH Center for Genomic Medicine
2018 BDSRA Cotman MGH Center for Genomic Medicine2018 BDSRA Cotman MGH Center for Genomic Medicine
2018 BDSRA Cotman MGH Center for Genomic Medicine
 
2017 BDSRA Cotman, Chandrachud, Hillje, Ilo, Sci, Nowell and Klein CLN2, CLN3...
2017 BDSRA Cotman, Chandrachud, Hillje, Ilo, Sci, Nowell and Klein CLN2, CLN3...2017 BDSRA Cotman, Chandrachud, Hillje, Ilo, Sci, Nowell and Klein CLN2, CLN3...
2017 BDSRA Cotman, Chandrachud, Hillje, Ilo, Sci, Nowell and Klein CLN2, CLN3...
 
Preclinical drug discovery and development
Preclinical drug discovery and developmentPreclinical drug discovery and development
Preclinical drug discovery and development
 
Methods of Research
Methods of Research Methods of Research
Methods of Research
 
2018 BDSRA Cotman CLN3
2018 BDSRA Cotman CLN32018 BDSRA Cotman CLN3
2018 BDSRA Cotman CLN3
 
Jncl augustine
Jncl augustineJncl augustine
Jncl augustine
 
antibody engineering and xenotransplantation
antibody engineering and xenotransplantation antibody engineering and xenotransplantation
antibody engineering and xenotransplantation
 
2014 BDSRA Davidson LINCL
2014 BDSRA Davidson LINCL2014 BDSRA Davidson LINCL
2014 BDSRA Davidson LINCL
 
Sjogren ppt
Sjogren pptSjogren ppt
Sjogren ppt
 
NEURODEGENERATIVE DISEASE
NEURODEGENERATIVE DISEASENEURODEGENERATIVE DISEASE
NEURODEGENERATIVE DISEASE
 
236 Understanding Systemic Lupus Erythematosus. A Qualitative Study Of Women ...
236 Understanding Systemic Lupus Erythematosus. A Qualitative Study Of Women ...236 Understanding Systemic Lupus Erythematosus. A Qualitative Study Of Women ...
236 Understanding Systemic Lupus Erythematosus. A Qualitative Study Of Women ...
 
Aspect of-stem-cell-based-therapies-kwang-yul-cha
Aspect of-stem-cell-based-therapies-kwang-yul-chaAspect of-stem-cell-based-therapies-kwang-yul-cha
Aspect of-stem-cell-based-therapies-kwang-yul-cha
 
Invivo pharmacology
Invivo pharmacologyInvivo pharmacology
Invivo pharmacology
 
Lecture 1 & 2.pdf
Lecture 1 & 2.pdfLecture 1 & 2.pdf
Lecture 1 & 2.pdf
 
2018 BDSRA Gray CLN1
2018 BDSRA Gray CLN12018 BDSRA Gray CLN1
2018 BDSRA Gray CLN1
 
Animal Models for Therapeutic Strategies
Animal Models for Therapeutic StrategiesAnimal Models for Therapeutic Strategies
Animal Models for Therapeutic Strategies
 
M.Sc; Transgenic mice as a model of human diseases.pptx
M.Sc; Transgenic mice as a model of human diseases.pptxM.Sc; Transgenic mice as a model of human diseases.pptx
M.Sc; Transgenic mice as a model of human diseases.pptx
 
Lessons from-geron 2014
Lessons from-geron 2014Lessons from-geron 2014
Lessons from-geron 2014
 

Plus de Batten Disease Support and Research Association

Plus de Batten Disease Support and Research Association (18)

2018 BDSRA Gayko
2018 BDSRA Gayko2018 BDSRA Gayko
2018 BDSRA Gayko
 
2018 BDSRA Whiting CLN2
2018 BDSRA Whiting CLN22018 BDSRA Whiting CLN2
2018 BDSRA Whiting CLN2
 
2018 BDSRA Vierhile
2018 BDSRA Vierhile2018 BDSRA Vierhile
2018 BDSRA Vierhile
 
2018 BDSRA Storch CLN7
2018 BDSRA Storch CLN72018 BDSRA Storch CLN7
2018 BDSRA Storch CLN7
 
2018 BDSRA Hughes CLN6
2018 BDSRA Hughes CLN62018 BDSRA Hughes CLN6
2018 BDSRA Hughes CLN6
 
2018 BDSRA Roine CLN3
2018 BDSRA Roine CLN32018 BDSRA Roine CLN3
2018 BDSRA Roine CLN3
 
2018 BDSRA Roberge
2018 BDSRA Roberge 2018 BDSRA Roberge
2018 BDSRA Roberge
 
2018 BDSRA Circumvent Pharmaceuticals CLN1
2018 BDSRA Circumvent Pharmaceuticals CLN12018 BDSRA Circumvent Pharmaceuticals CLN1
2018 BDSRA Circumvent Pharmaceuticals CLN1
 
2018 BDSRA Cooper, Nelvagal
2018 BDSRA Cooper, Nelvagal2018 BDSRA Cooper, Nelvagal
2018 BDSRA Cooper, Nelvagal
 
2018 BDSRA Feuerborn
2018 BDSRA Feuerborn2018 BDSRA Feuerborn
2018 BDSRA Feuerborn
 
2018 BDSRA Dang Do CLN3
2018 BDSRA Dang Do CLN32018 BDSRA Dang Do CLN3
2018 BDSRA Dang Do CLN3
 
2017 BDSRA Storch and Danyukova CLN7
2017 BDSRA Storch and Danyukova CLN72017 BDSRA Storch and Danyukova CLN7
2017 BDSRA Storch and Danyukova CLN7
 
2017 BDSRA Stehr and van der Putten, CLN3
2017 BDSRA Stehr and van der Putten, CLN32017 BDSRA Stehr and van der Putten, CLN3
2017 BDSRA Stehr and van der Putten, CLN3
 
2017 BDSRA Autti, U. Roine, T. Roine, Aberg, Tokola, Balk, Hakkarainen, Manne...
2017 BDSRA Autti, U. Roine, T. Roine, Aberg, Tokola, Balk, Hakkarainen, Manne...2017 BDSRA Autti, U. Roine, T. Roine, Aberg, Tokola, Balk, Hakkarainen, Manne...
2017 BDSRA Autti, U. Roine, T. Roine, Aberg, Tokola, Balk, Hakkarainen, Manne...
 
2017 BDSRA Trometer, Potier, Cournoyer, and Schermer
2017 BDSRA Trometer, Potier, Cournoyer, and Schermer2017 BDSRA Trometer, Potier, Cournoyer, and Schermer
2017 BDSRA Trometer, Potier, Cournoyer, and Schermer
 
2017 BDSRA Mole, Band, Codd and West CLN3, CLN6, CLN7
2017 BDSRA Mole, Band, Codd and West CLN3, CLN6, CLN72017 BDSRA Mole, Band, Codd and West CLN3, CLN6, CLN7
2017 BDSRA Mole, Band, Codd and West CLN3, CLN6, CLN7
 
2017 BDSRA Dearborn, Wong and Sands CLN1
2017 BDSRA Dearborn, Wong and Sands CLN12017 BDSRA Dearborn, Wong and Sands CLN1
2017 BDSRA Dearborn, Wong and Sands CLN1
 
2017 BDSRA Berg CLN3
2017 BDSRA Berg CLN32017 BDSRA Berg CLN3
2017 BDSRA Berg CLN3
 

Dernier

Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfMayuriGamit2
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUKanhu Charan
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxVeereshDemashetti
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfNetHelix
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...Genesis Institute of Pharmacy, Radhanagari.
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 

Dernier (20)

Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
 
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptx
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdf
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 

2016 BDSRA Katz & Johnson All NCL types

  • 1. All Types of NCL Canine Models for NCL Therapy Development Martin L. Katz and Gary S. Johnson, School of Medicine and College of Veterinary Medicine, University of Missouri Introduction: Dog models for the neuronal ceroid lipofuscinoses (NCLs or Batten disease) will be useful for evaluating the efficacy of potential therapeutic interventions for treating these diseases. The NCLs result from mutations in at least 13 different genes. Different approaches to therapy are going to be required to treat the different forms of NCL. Therefore, it will be important to have suitable animal models for each of the forms of NCL. A dog model for the CLN2 form of Batten disease played a critical role in the development of an effective enzyme replacement therapy currently being used to treat children with this disorder. This has proven the utility of dog models in pre- clinical studies required before approval can be obtained for conducting human clinical trials. Our goal is to develop dog models for each of the forms of NCL that can be used for therapeutic intervention testing in preparation for conducting human clinical trials. Acknowledgements: This work was made possible by the many dog owners who contributed samples from their pets and the veterinarians who collected postmortem tissues. Numerous research personnel contributed to the disease characterizations and mutation identifications. Among them are Tomoyuki Awano, Douglas Sanders, Dennis O’Brien, Liz Hansen, Fabiana Farias, Jenny Guo, Douglas Gilliam, and Ana Kolicheski. Others who contributed to this work are listed on the laboratory website http://medicine.missouri.edu/neurodegenerativediseases/publications.php Support for some of this work was provided by the BDSRA and the American Kennel Club Canine Health Foundation. Establishing Canine NCL Models: Naturally occurring canine NCLs identified to date: Significance: • A Dachshund model for the CLN2 form of NCL was used to demonstrate the efficacy of enzyme replacement therapy that resulted in the recent successful completion of human clinical trials of this treatment in children by BioMarin Pharmaceutical. • Using this same model, gene therapy to the central nervous system was also found to be effective in treating this disease. This method of treatment may be tested in children in the future. • Currently we have preserved canine semen for the CLN2 and CLN5 forms of Batten disease. • We are screening dogs with the other forms of NCL to obtain semen as a resource for breeding affected dogs. • We also continue to search for dogs with different forms of NCL that correspond to the remaining forms of NCL. We have DNA samples from several other dog breeds with NCL for which we are seeking to causative mutation. • We plan to establish a canine NCL models resource center that will be able to generate dogs affected with each of the forms of NCL. • We developed a panel of biomarkers of NCL disease progression in dogs that can be used in testing for the therapeutic efficacy of treatments using the dog models.